Parexel launches advisory service dedicated to Chinese market

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Tuangtong)
(Image: Getty/Tuangtong)

Related tags: China, Parexel, Clinical trials

Parexel is launching a new advisory service to help clients navigate the market opportunities in China.

The biopharmaceutical services provider has launched a new China Advisory Service. The offering includes overall strategy, agency engagement and agreements, early development, clinical operations, and regulatory, market access, and commercial strategies support.

Several regulatory changes in China over the past few years​ are expected to accelerate drug development timelines.

Earlier this year, the Chinese Premier Li Keqiang announced​ several developments during an executive meeting of the State Council of the People's Republic of China last month. Of the highlighted developments, plans include those “to enhance quality supervision,” establish “intensified on-site inspection of foreign drugs’ production,” and double down on counterfeit drugs, according to the release from the State Council.

Read more: Chinese gov't outlines changes to import tariff, clinical trial applications, IP protection

China also now accepts clinical trial data from other countries following a new guideline released last yea​r that aims to reform the management of clinical trials.

Over the next 10 years, the Chinese market is expected to see “high growth,”​ as health care currently accounts for just 7% of the overall government expense – leaving room to expand, Mingping Zhang, vice president, technical, Parexel Consulting, told us in June.

The Chinese pharmaceutical market recently outpaced Japan to become the second largest market globally.

Parexel has been operating in China for more than 19 years and employs more than 1,400 employees in seven offices across the country.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars